News & Events

Impact of Androgen Stimulation and Darolutamide Inhibition
Jan 27, 2023

We are thrilled to congratulate the team around Bernard Haendler and Ekaterina Nevedomskaya on their recent publication of a multi-omics study on the proximal changes of androgen-stimulated prostate cancer cells treated with the next-generation nonsteroidal antiandrogen (NSAA) darolutamide.

Darolutamide acts as a selective competitive silent antagonist of the androgen receptor (AR), binding androgenic hormones such as testosterone or dihydrosterone in the cytosplasm, which then translocates into the nucleus and regulates gene expression as a transcription factor.

As therapy resistance eventually occurs in late-stage tumors, a deeper understanding of the molecular mechanisms involved in response and resistance to AR inhibitors is crucial for furthering our understanding of current drugs and determining potential liabilities in future targeted therapies.

In this study, the team focused on mechanisms proximal to the AR, as this nuclear hormone receptor plays a crucial role at different stages of prostate cancer. They evaluated the impact of androgen stimulation and darolutamide on the prostate cancer proteome by label-free MS-based quantitative proteome profiling, transcriptomics and other techniques such as CETSA-HT and ChIP-seq.

Their findings indicate a high level of concordance between proteomic and transcriptomic data, but also revealed instances of post-transcriptional regulation of protein abundance. This highlights the importance of utilizing both proteomic and transcriptomic data to gain a more complete understanding of the biological processes involved in prostate cancer.

If you're interested in learning more about this project, you can find the corresponding paper from the linke below its open access. Additionally, you can learn more about proteomics and our services here on our website or by reaching out to us directly.

Nevedomskaya, E. et al. Comparative Proteomic and Transcriptomic Analysis of the Impact of Androgen Stimulation and Darolutamide Inhibition. Cancers 15, 2 (2023). DOI: 10.3390/cancers15010002